Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

huC242-DM1

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
2005
2005
1429 Several anti-tumor antibody-maytansinoid conjugates, commonly called TAPs (tumor-activated prodrugs) are currently under… Expand
Highly Cited
2004
Highly Cited
2004
The humanized monoclonal antibody maytansinoid conjugate, cantuzumab mertansine (huC242-DM1) that contains on average three to… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2003
2003
L'invention concerne une formulation stable destinee a huC242-DM1, un anticorps conjugue a un agent cytotoxique. 
2001
2001
  • S. Smith
  • Current opinion in molecular therapeutics
  • 2001
  • Corpus ID: 22143103
C242-DM1 is a tumor-activated immunotoxin under development by GlaxoSmithKline plc (formerly SmithKline Beecham plc), under… Expand